Related references
Note: Only part of the references are listed.Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma
Anna Pavlick et al.
CANCER IMMUNOLOGY RESEARCH (2020)
First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors
Mikiya Ishihara et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
Poly-ICLC, a multi-functional immune modulator for treating cancer
Hussein Sultan et al.
SEMINARS IN IMMUNOLOGY (2020)
Poly-IC enhances the effectiveness of cancer immunotherapy by promoting T cell tumor infiltration
Hussein Sultan et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance
Daisuke Muraoka et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial
Elizabeth A. Mittendorf et al.
CLINICAL CANCER RESEARCH (2019)
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
Ken Kato et al.
LANCET ONCOLOGY (2019)
Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients
M. E. Rodriguez-Ruiz et al.
ANNALS OF ONCOLOGY (2018)
MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial
Brigitte Dreno et al.
LANCET ONCOLOGY (2018)
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
Yelena Y. Janjigian et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Vaccination with poly (IC: LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer
Shikhar Mehrotra et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
NY-ESO-1 autoantibody as a tumor-specific biomarker for esophageal cancer: screening in 1969 patients with various cancers
Yoko Oshima et al.
JOURNAL OF GASTROENTEROLOGY (2016)
Vaccine adjuvants as potential cancer immunotherapeutics
Burcu Temizoz et al.
INTERNATIONAL IMMUNOLOGY (2016)
Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial
Johan F. Vansteenkiste et al.
LANCET ONCOLOGY (2016)
Vaccine adjuvant uses of poly-IC and derivatives
Karen Ao Martins et al.
EXPERT REVIEW OF VACCINES (2015)
Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients
Shinichi Kageyama et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion
Yared Hailemichael et al.
NATURE MEDICINE (2013)
Limited expression of cancer-testis antigens in renal cell carcinoma patients
Norihito Soga et al.
MOLECULAR AND CLINICAL ONCOLOGY (2013)
Peptide Vaccine Induces Enhanced Tumor Growth Associated with Apoptosis Induction in CD8+ T Cells
Daisuke Muraoka et al.
JOURNAL OF IMMUNOLOGY (2010)
Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432
Masatoshi Aoki et al.
VACCINE (2009)
HER2-specificT-cell immune responses in patients vaccinated with truncated HER2 protein complexed with nanogels of cholesteryl pullulan
Shigehisa Kitano et al.
CLINICAL CANCER RESEARCH (2006)
Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients:: Correlation with antibody responses
S Gnjatic et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues
AA Jungbluth et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Share Paper
